![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiBc21Y3qx_32JIulpVBKBEGmyMYKvVGv7l5GD_Ot8jdmQyyv63Jd9I3b4YFgVOh5yJ1pVdtPwMUoJaeKFz9Bzrefc5ajA5F5pOKKkK6R2riL48an0cVPnclALOkxg_sza28zGkZXDIudM/s200/logo_aranesp_home.gif)
Aranesp® for the treatment of anemia caused by chronic kidney failure or chemotherapy
Erythropoietin is a glycoprotein which stimulates red blood cell production. It is produced in the kidney and stimulates the division and differentiation of committed erythroid progenitors in the bone marrow. Epogen® has the same biological effects as endogenous erythropoietin.
Kineret® for the reduction in signs and symptoms of rheumatoid arthritis in adult patients who have an inadequate response to other disease modifying antirheumatic drugs.
Refludan® for the treatment of heparin-induced thrombocytopenia type II and thromboembolic disease in adults mandating parenteral antithrombin therapy - an infrequent but potentially life-threatening response to heparin therapy
Valcyte® an antiviral agent prescribed to slow the spread of and prevent cytomegalovirus infection in immunocompromised individuals, including transplant recipients and people with AIDS.
Invirase® a protease inhibitor developed for use in combination with other medicines, such as AZT, to fight the onset of AIDS in people who are HIV positive
Fuzeon® The first in a new class of anti-HIV drug, known as fusion inhibitors, that prevents the HIV virus from infecting healthy T-cells. The active ingredient in Fuzeon™ is a 36 string amino acid peptide that has been considered the most complex drug ever chemically synthesized at such a large scale.
Innohep® For the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with the oral anticoagulant warfarin sodium.
Thalidomide® approved in Australia, New Zealand, Turkey, Israel, South Korea and Thailand for the treatment of multiple myeloma after the failure of standard therapies and the acute treatment of cutaneous manifestations of moderate to severe erythema nodosum leprosum.
Vidaza® for the treatment of all five subtypes of Myelodysplastic Syndromes (MDS) these subtypes include: refractory anemia or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).
Macugen® the first anti-VEGF inhibitor to be approved by the FDA for the treatment of wet age-related macular degeneration.
Efaproxyn™ the first synthetic small molecule designed to sensitize hypoxic, or oxygen deprived, areas of tumors during radiation therapy by facilitating the release of oxygen from hemoglobin, the oxygen-carrying protein contained within red blood cells, and increasing the level of oxygen in tumors. Currently in Phase III trials.